0119 Aclaris RA readout
BioCentury & Getty Images

Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

Jan 20, 2021 | 1:58 AM GMT

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it

Read the full 608 word article

How to gain access

Continue reading with a
two-week free trial.